At SEB"s Nordic Seminar, CEO Ulrik Harrysson outlined the company"s strategy towards becoming a standard of care, and highlighted key advancements such as the strengthened OEM partnerships, vastly improved pricing points and transition to time-based licenses. With the planned launch of SyMRI 3D in Q1, combined with no larger investment needs, we believe 2024 could be an exciting year for SyntheticMR.

Länk till analysen